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Background: It has been reported that repeated intravenous injections of a relatively large amount of Leishmania
amazonensis amastigote extract (LaE) in BALB/c mice exacerbates the infection of these mice by Leishmania
braziliensis. The identification of the extract active principle(s) through physicochemical purification often involves
dilution and losses of protein in the course of successive purification procedures. The large amount of the extract
required to induce the phenomenon, therefore, hinders the carrying out of experiments aimed at identifying the
active molecule(s) through extract purification. In the present work, a dose–response experiment was done to find
out if smaller amounts of LaE than that necessary to be used by the intravenous route would reproduce the
phenomenon when injected by the intradermal route. In addition, it was also investigated whether a Leishmania
braziliensis amastigote extract (LbE) would exert the same effect and whether the effect would occur in C57BL/6 mice.
Results: It was found that a single injection of either LaE or LbE containing 5 μg of protein was capable of enhancing
the infection in BALB/c but not in C57BL/6 mice. In addition, it was observed that the largest tested doses of LbE
(containing 30 and 180 μg of protein) failed to enhance the infection by L. braziliensis, whereas all doses of LaE
enhanced equally that infection.
Conclusions: Those results indicate the possible existence in LbE, and not in LaE, of molecules that interfere with the
extract infection-enhancing activity when it is injected in large amounts, and that the inoculation of Leishmania extracts
through the intravenous and intradermal routes potentiate the infection by L. braziliensis through the same mechanism.
Keywords: Leishmania amazonensis, Leishmania braziliensis, Intradermal antigen, Infection enhancement, LeishmaniasisBackground
Leishmaniases are zoonosis caused by different species
of protozoa of the genus Leishmania. In Brazil, Leish-
mania braziliensis is the most prevalent etiologic agent
in the northeast region and Leishmania amazonensis is
the most widely distributed species [1,2]. Both species can
cause American cutaneous leishmaniasis (ACL), which is
in geographic expansion in Brazil, with the incidence in-
creasing from 10.5/100,000 inhabitants in 1985 to 18.6/* Correspondence: lain.carvalho@gmail.com
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stated.100,000 inhabitants in 2005. The disease has currently
been reported in all regions of the country, but, with an
average of 28,568 annual cases, the northeastern region,
one of the poorest of the country, had the highest inci-
dences between 1985 and 2005. In 2001, for example, the
incidence in that region was 93.8 cases/100,000 inhabi-
tants [3].
ACL has four distinct clinical manifestations: cutaneous,
mucosal, disseminated cutaneous, and diffuse cutaneous.
Cutaneous, mucosal, and disseminated leishmaniases are
caused in Brazil mainly by L. braziliensis, while L. amazo-
nensis, in addition to cutaneous leishmaniasis, causes, in a
minority of cases, diffuse cutaneous leishmaniasis [4].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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de Araújo et al. BMC Research Notes 2014, 7:70 Page 2 of 8
http://www.biomedcentral.com/1756-0500/7/70BALB/c mice are partially resistant to infection with L.
braziliensis: they do not develop severe injuries and usually
cure the infection with a mixed cellular immune response
[5]. On the other hand, when infected by Leishmania
major or L. amazonensis, either subcutaneously in the foot
pad [6-8] or intradermally in the external ear [1,9], they de-
velop a Th2-cell response and progressive skin lesions,
which tend to be more necrotic in L. major-infected mice
[10,11], and eventually die of the disease [11].
The susceptibility to the leishmanial infection depends
not only on the Leishmania species, but also on the gen-
etic background of the mouse. Thus, C57BL/6, CBA and
BALB/c mice are resistant to L. braziliensis and suscep-
tible to L. amazonensis [12,13]. On the other hand, con-
trasting with BALB/c mice, C57BL/6 and CBA mice are
resistant to L. major [10].
The outcome of the infection of BALB/c mice by L.
braziliensis, however, can be completely changed by treat-
ing them with four biweekly intravenous injections of L.
amazonensis amastigote extract containing 200 μg of pro-
tein and starting one week before the infection: the animals
thus treated become fully susceptible to the disease. On the
other hand, this phenomenon did not take place when a L.
braziliensis amastigote extract or a L. amazonensis promas-
tigote extract was used instead of the L. amazonensis
amastigote extract [8], or when lower amounts of L.
amazonensis amastigote extract were used [Silva VMG,
unpublished].
The identification of the extract active principle by its
purification to homogeneity very often entails its dilu-
tion or partial loss during two or more consecutive puri-
fication steps. For this reason, it would be important to
find out whether the infection-enhancing phenomenon
could be observed with lower amounts of the extract
than that required by the intravenous route if it was
injected by another route. The aim of the present study
was to investigate whether lower doses of the L. amazo-
nensis amastigote extract (LaE) could modulate the L.
braziliensis infection in BALB/c and C57BL/6 mice when
injected by the intradermal route and whether this effect
could be observed with L. braziliensis amastigote extract
(LbE). It was found that a single injection of either LaE or
LbE in a dose two orders of magnitude lower than that
needed intravenously [8] induced the phenomenon in
BALB/c mice. In addition, the highest doses of LbE failed
to enhance the infection in BALB/c mice, and none of the
tested doses enhanced the infection in C57BL/6 mice.
Results
Effect of the intradermal injection of LaE on L. braziliensis
infection in BALB/c mice
In previous experiments carried out by our research
group, an amount of LaE containing at least 200 μg of
protein was required to enhance a L. braziliensis cutaneousinfection in BALB/c mice ([8]; Silva et al., unpublished
results). The requirement to inject this relatively large
amount of extract in each mouse, in experiments with 6
to 8 mice per group, practically precludes the purifica-
tion of the active principle from research laboratory’s
parasite batches by means of biophysical techniques,
such as electrophoresis and liquid chromatography. One
of the aims of the present work, therefore, was to find out
whether smaller amounts of extract, when injected by an-
other route, would also mediate the phenomenon.
In a first experiment, doses of extract containing 1.25,
5, and 20 μg of protein were used. It was found that a
single intradermal injection of LaE, containing amounts of
protein as little as 1.25 μg, led to significant increases in
the sizes of the lesions caused by L. braziliensis (Figure 1A)
and in tissue parasitism (Figure 1B). The smallest dose
tested—1.25 μg—led to significant increases in lesion
parasitism (Figure 1B), but not in lesion sizes (Figure 1A).
Dose-responses of the effect of LbE and LaE intradermal
injections in L. braziliensis-infected BALB/c mice
We next decided to find out how comparable were the
results that could be produced by administering the ex-
tract through the intradermal route with those previ-
ously published by Silvia and collaborators, who injected
the extract by the intravenous route [8]. Because, when
injected intravenously, the LbE failed to enhance an L.
braziliensis infection, we investigated whether the same
would occur when the LbE was injected intradermally.
In this second experiment, doses of extracts containing
5, 30 and 180 μg of protein were used because one of
them (the dose of 5 μg of protein) fell within the range
of LaE doses shown in the present work to enhance the
infection (doses containing 1.25 to 20 μg of protein),
and another of them was 9 folds higher (the dose of
180 μg of protein) than the highest amount (20 μg) of
LaE that we had tested so far.
The injection of LbE containing 5 μg of protein sig-
nificantly increased the size of the lesions caused by L.
braziliensis in BALB/c mice (Figure 1C). This did not
occur when the dose was augmented to 30 and 180 μg
of protein: the sizes of lesions of mice injected with
these latter doses of LbE did not differ significantly from
those of mice injected only with saline (Figure 1C).
These findings contrasted markedly with what was ob-
served when the mice were injected with the same doses
of LaE: all these doses of LaE (containing 5, 30 and 180
of protein) caused a significant increase in lesion sizes
(Figure 1A).
As expected from the results described above, the re-
duction in lesion size with the increasing doses of LbE
was statistically significant (Table 1). Thus, the group of
mice injected with the 5 μg of protein LbE dose signifi-
cantly differ from the groups of mice injected with the
Figure 1 Effect of intradermal injection of L. amazonensis (LaE) and L. braziliensis (LbE) extracts in the infection of BALB/c mice by L.
braziliensis. A and C, lesion sizes in groups of five to eight BALB/c mice injected with saline and different doses of LaE (A) or LbE (C). B and D,
number of parasites per lesion as estimated by limiting dilution, at the sixth week after infection, of the same mice whose lesion sizes are
depicted in A and C, respectively. The animals were treated with a single intradermal injection of saline or of the doses of extracts indicated
above the graphs in A and C or below the X axis in B and D. One week later they were infected with 107 L. braziliensis promastigotes in the
stationary phase of growth. The lines in A and C join the median values of the results from each group in each week, and the vertical bars
represent the interquartile interval. Each symbol in B and D represents the result obtained from a single animal. The results of two independent
experiments are shown. Symbols and lines corresponding to the results from one experiment are dark blue and the lines are broken; from the
other experiment the symbols and lines are red and the lines are continuous. Comparisons between the groups of extract-injected and the group
of saline-injected mice were performed by Mann–Whitney U test [level of significance when comparing lesion sizes (A and C) = 0.0056; when
comparing lesion parasitism (B and D) = 0.0167]. *P < 0.005; **P < 0.001.
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test) and with the 180 μg dose (as determined by Fisher’s
exact probability and Mann–Whitney U tests; Table 1).
Contrasting with the described above for the LbE, no
statistically significant difference in lesion sizes was ob-
served between the groups of mice injected with 5 and
180 μg doses of LaE (Figure 1A and Table 1). The lesion
sizes in the group of mice injected with the 30 μg dose
of LaE significantly differ from those of the mice injected
with the 5 μg dose of that extract, as shown by Mann–
Whitney U test (Table 1). However, this dose led to larger
lesions than the 5 μg dose (Figure 1A), and not to the op-
posite, as happened with LbE.
All doses of LbE increased tissue parasitism (Figure 1D).
However, the proportion of mice in which the injection ofthe lowest amount of LbE (containing 5 μg of protein) led
to more than 20,000 parasites per lesion (8 out of 8 mice)
was significantly larger (p = 0.007, Fisher’s exact probabil-
ity test, significance level = 0.025; Table 1) than the pro-
portion of the mice in which the highest amount (with
180 μg of protein) led to more than 20,000 parasites per
lesion (2 out of 8 mice; Figure 1D). In fact, 8 out of 8 mice
that received LbE containing 5 μg of protein had more
than 1,500,000 parasites per lesion (Figure 1D). On the
other hand, all doses of LaE led to similar increases in tis-
sue parasitism (Figure 1B).
In accordance with the data described above, LbE was
less active than LaE in terms of increasing lesion sizes in
the dose of 30 μg (as shown by Fisher’s exact probability
test; Table 1) and in the dose of 180 μg (in accordance
Table 1 Statistical significance of differences in the potentiating effect of L. amazonensis (LaE) and L. braziliensis (LbE)
extracts on L. braziliensis infection, and between different doses of the same extract
Tested extracts in
compared groups
Measured outcome Protein amount
in extracts (μg)






0.5000 Fisher’s exact probability
30 0.0079 Mann–Whitney U
0.0035* Fisher’s exact probability
180 0.0046 Mann–Whitney U





0.5000 Fisher’s exact probability
30 0.0043 Mann–Whitney U
0.0385 Fisher’s exact probability
180 0.0136 Mann–Whitney U






1.0000 Fisher’s exact probability
5, 180 0.2263 Mann–Whitney U





1.0000 Fisher’s exact probability
5, 180 0.1902 Mann–Whitney U






0.0070 Fisher’s exact probability
5, 180 0.0019 Mann–Whitney U





0.0769 Fisher’s exact probability
5, 180 0.0039 Mann–Whitney U
0.0070 Fisher’s exact probability
*Boldface values are statistically significant.
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Whitney U tests; Table 1). In terms of enhancing lesion
parasitism, again LbE was less active than LaE in the dose
of 30 μg (as shown by Mann–Whitney U test; Table 1) and
in the dose of 180 μg (in accordance with both Fisher’s
exact probability and Mann–Whitney U tests; Table 1). No
statistically significant differences between LbE and LaE
was observed when they were administered in the dose of
5 μg of protein (Table 1).
Effect of the intradermal injection of LaE or LbE on L.
braziliensis infection in C57BL/6 mice
When injected intravenously, LaE failed to potentiate the
infection by L. braziliensis in C57BL/6 mice [8]. In order
to further compare the results that could be obtainedthrough injection of the extract through the intradermal
route with those previously described with injection by
intravenous route, C57BL/6 mice were injected by the
intradermal route with a dose of LaE and of LbE contain-
ing 5 μg of protein, an amount that clearly enhanced the
infection in BALB/c mice (Figures 1A and 1C). As a posi-
tive control of the infection-enhancing activity of the LaE,
this extract was also injected into BALB/c mice.
The infection of the C57BL/6 mice by L. braziliensis
led to quickly resolving lesions (as judged by their sizes),
with less than 1 mm of thickening of the mouse foot pads,
that started to subside after the second week but were still
perceptible in most mice, after six weeks, as less than
0.2 mm foot pad enlargement (Figure 2 and data not
shown).
Figure 2 Lesions sizes in L. braziliensis-infected C57BL/6 mice in
which L. amazonensis and L. braziliensis extracts had been
injected. The animals (n = 4–6 per group) were treated with
intradermal injections of the vehicle (Saline C57BL/6) or of L.
amazonensis (LaE BALB/c and LaE C57BL/6) or L. braziliensis (LbE
C57BL/6) extracts containing 5 μg of protein, one week before being
infected with 107 L. braziliensis promastigotes in the stationary phase
of growth. The lines in A and C join the median values of the results
from each group in each week, and the vertical bars represent the
interquartile interval. Comparisons between the groups of extract-
injected and the group of saline-injected mice were performed by
Mann–Whitney U test (level of significance = 0.0056). *P < 0.001.
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acerbated the cutaneous disease caused by L. braziliensis
in those mice (Figure 2).
Discussion
As has been shown for the intravenous injection, the
intradermal injection of LaE in BALB/c mice potentiated
the infection by L. braziliensis. However, when adminis-
tered by the intradermal route, a dose of LaE two orders
of magnitude lower (1.25 μg) than the dose that was able
to promote the infection by the intravenous route
(200 μg; [8]) was enough to produce the effect. Differ-
ences in Leishmania infection outcomes depending on
the route of administration of the antigen have been ob-
served [4,14,15]. However, comparisons between immuni-
zations with Leishmania antigens by the intravenous and
the intradermal routes have not been so far reported.
The effect on the size of the lesions caused by the
1.25 μg of protein dose was very apparent. However, the
effect, at this low dose of the extract, was not statistically
significant (p = 0.0102, Mann–Whitney U test), perhaps
due to the fact that three different comparisons had been
made (namely 1.25 μg vs saline, 5 μg vs saline, and 20 μg
vs saline) in three different occasions (in which differences
in lesion sizes could be expected: the 4th, the 5th, and the
6th weeks). These multiple comparisons reduced the level
of significance to 0.0056. The conspicuousness of theextract effect in this low dose, however, increases the feasi-
bility of the physicochemical purification of its active
principle from amounts of extract easily obtainable in a
research facility.
When injected intravenously, the enhancing effect on
the infection of Leishmania extracts depends on the
presence of IL-4 [8]. The mechanism of this enhance-
ment when the antigen is injected into the intradermal
space, however, has still to be clarified. Preliminary ex-
periments showed no differences in the production of
either IL-4 or IL-10 by anti-CD3 - stimulated cells of
lesion-draining lymph nodes (unpublished). The possibil-
ity that the effect could be mediated by TGF-β-producing
Treg cells is open to investigation. Supporting this hypoth-
esis, it has been reported that TGF-β exacerbates the in-
fection of BALB/c mice by L. amazonensis [16,17]. If the
most likely underlying mechanism, i. e., the biasing of the
BALB/c mouse immune response towards an infection-
permissive one by antigens in the LaE is true, the C57BL/
6 immune system would respond to these antigens in a
different way, as the LaE did not increase lesion sizes in
C57BL/6 mice.
It was also demonstrated in the present work that the
injection of LbE by the intradermal route potentiates the
infection by L. braziliensis. However, contrasting to what
was observed with LaE, a statistically significant effect
was only seen with a lower dose of the extract and not
with the larger doses. The infection-enhancing activity
of the largest doses of LbE was indeed significantly lower
than the activivities of the same doses of LaE. This finding
is consistent with that reported by Silva and collaborators
[8], who found that LbE, when repeatedly administered by
the intravenous route in a relatively high dose, did not ex-
acerbate the infection of BALB/c mice by L. braziliensis.
This dose-dependent difference between LaE and LbE in
affecting the course of the disease could be ascribed to the
coexistence in LbE of molecules that could induce pro-
tective immune responses and of others that could induce
a permissive immune response, which would have dif-
ferent dose (of the extract)-response curves. Thus, anti-
gens that could induce a protective immune response
would be recognized by the immune system only when
high amounts of LbE was introduced in the organism
(and identical or similar antigens would not be present
or be present in an insufficient amount in the LaE),
whereas in low amounts of LbE other antigens, which could
be present in higher concentrations in the extract, would
induce a susceptibility-associated immune response. This
hypothesis is amenable to investigation, e.g. through experi-
ments using LbE fractions and/or by testing the effect of
mixtures of low amounts of LaE with high amounts of LbE.
These results indicate, therefore, that the two Leishmania
species may differ in terms of the presence, or of the rela-
tive amounts, of antigens against which the BALB/c
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sponse. Whether this difference would account for the
fact that a minority of human beings with cutaneous lesions
caused by L. amazonensis develops a progressive disease, a
phenomenon that does not occur when the cutaneous le-
sions are caused by L. braziliensis, is open to speculation.
The progressive disease would be accounted by L. amazo-
nensis parasites producing mainly infection-promoting
molecules, whose recognition as such would also depend
on the genetic background of the host. It is tempting to
make a parallel between the fact that only the BALB/c, and
not the C57BL/6 mice, had their disease worsened by
Leishmania extracts and the fact that only a minority of
human beings with clinically manifested L. amazonensis
infection develop the diffuse, progressive disease.
Evidence for the existence of different immunomodu-
latory Leishmania molecules that might potentiate the
infection have been reported [17-22]. A preliminary frac-
tionation of the LaE by polyacrylamide gel electrophoresis
followed by electroelution of proteins from gel fragments
and analysis of the eluted protein fractions by mass spec-
trometry led to the conclusion that at least three different
Leishmania proteins are able to enhance the Leishmania
infection in BALB/c mice when injected intradermally.
One of the proteins present in a fraction with infection-
enhancing activity was the Leishmania homologue of re-
ceptors for activated C kinase (LACK), which has been
described as having immunomodulatory activity [19]. Two
other fractions with Leishmania infection-enhancing ac-
tivity contained proteins to which no immunomodulatory
activity has been attributed so far (unpublished).
Different L. braziliensis isolates may cause different inten-
sities of cutaneous disease and lesions with distinct histopa-
tological patterns [5,23]. The isolate we used causes a
self-healing cutaneous disease when inoculated in the foot
pad of BALB/c mice, with lesions smaller than 1 mm that
usually subside after two or three weeks and are bearly
measurable after six weeks. However, about one in every
three or four mice develops a larger lesion, that also sub-
sides after six weeks (unpublished observations). It would
not be surprising if extracts prepared from different L. bra-
ziliensis isolates would differ in their infection-enhancing
activity.
Moreover, the fact that a high amount of LbE is less ac-
tive in terms of inducing disease exacerbation than lower
amounts of the same extract and than the same high
amount of LaE can be used as evidence against the hy-
pothesis that the simple introduction of any Leishmania
antigen in the intradermal compartment would aggravate
the disease.
Conclusions
In conclusion, it was demonstrated in the present work
that a few micrograms of LaE or LbE, when injectedintradermally, are capable of aggravating the cutaneous
disease caused by L. braziliensis in BALB/c mice, and that
this phenomenon is not seen with larger amounts of LbE.
As has been reported previously, LaE failed to enhance
the infection in C57BL/6 mice when injected intraven-
ously [8]. As shown in the present work, this failure also
occurs when it is injected intradermally. In addition, the
LbE was less active in promoting the infection than the
LaE when injected in relatively high doses by either one
of the two routes ([8] and the present work). Taken to-
gether, these findings indicate that the same mechanism
is underlying the observed phenomena when the extract
is injected intravenously or intradermally.
Methods
Mice and ethical considerations
Specific-pathogen-free, 8 to 12 week-old BALB/c and
C57BL/6 mice were maintained at the animal facilities of
the Gonçalo Moniz Research Center, Oswaldo Cruz
Foundation, Salvador, Brazil, and were provided with ro-
dent diet and water ad libitum. All procedures were ap-
proved and conducted according to the institutional
Committee for Animal Care and Utilization.
Parasites and parasite extracts
L. amazonensis (MHOM/Br87/Ba125) and L. braziliensis
(MHOM/Br/3456) strains were used. Their infectivities
were maintained by regular inoculations of promasti-
gotes into susceptible BALB/c mice and golden ham-
sters, respectively.
Promastigotes, derived from tissue amastigotes, were
cultured at 23°C in Schneider’s medium (Sigma Chemical
Co., St. Louis, MO, USA), pH 7.2, supplemented with
50 μg/mL of gentamicin and 10% heat-inactivated fetal bo-
vine serum (FBS; Gibco Laboratories, Grand Island, NY)
for L. amazonensis or 20% FBS for L. braziliensis.
L. amazonensis and L. braziliensis axenic amastigotes
were obtained by the differentiation of promastigotes in
axenic cultures, as described elsewhere [24]. The amasti-
gotes were washed three times in ice cold sterile saline,
resuspended in saline, and lysed by exposure to ultra-
sound (10 1-minute, 300-W pulses, with 30-second inter-
vals in between, on ice; Sonifier Cell Disruptor; Branson
Sonic Power Company, Danbury, CT, USA). The lysates
were centrifuged at 16,000 g for 10 min at 4°C, the super-
natants were filtered on membranes with 0.22-μm diam-
eter pores (Millipore, São Paulo, Brazil) and immediately
aliquoted and stored at −70°C.
Infection and treatment of animals, determination of
lesion size and experimental design
L. braziliensis promastigotes (107), obtained from statio
nary-phase cultures, were subcutaneously inoculated
into one of the hind footpads of BALB/c or C57BL/6
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dermis of the dorsal region, with 50 μL of LaE or LbE
containing the amounts of protein that are indicated in
the Figures. The hind pad thicknesses were weekly mon-
itored with a digital caliper, until the sixth week post-
infection and the lesion sizes estimated by subtracting
the thickness of the uninfected pad from the thickness
of the infected pad. Parasite loads in the footpads were
estimated by limiting dilution [25] at the end of the ex-
periments, as described below.
Quantification of tissue parasitism
Briefly, the infected pads were macerated in Schneider’s
medium and centrifuged at 50 g for 10 min, at 4°C. The
supernatants were recentrifuged at 1,540 g for 10 min at
4°C, and the pellets were resuspended in Schneider’s
medium supplemented with 50 μg/mL gentamicin and
20% FBS. The suspension was serially diluted in 2-fold
dilutions and distributed in triplicate in 96-well culture
plates. The number of viable parasites in each footpad
was determined from the reciprocal of the highest dilu-
tion at which promastigotes could be detected after 7
days at 23°C and was expressed as the number of para-
sites per lesion.
Statistical analyses
The type of data distribution was determined by the
Shapiro-Wilk test. Because the distribution was found to
be non-Gaussian, non-parametric tests were used.
The statistical significance of differences in lesion size
and parasitism between pairs of groups of mice subjected
to different treatments were estimated by the Mann–
Whitney U test. As explained below, the number of com-
pared pairs in each experiment was taken into account to
calculate the significance level.
To additionally assess the statistical significance of dif-
ferences in lesion sizes, and in intensity of lesion parasit-
ism, between the groups of mice that had received 5 and
30 μg of extract, between the groups of mice that had re-
ceived 5 and 180 μg of extract, and between the groups of
mice that had received LbE and LaE, these groups of mice
were stratified into two pairs of categories: mice with le-
sions larger than 1 mm and mice with lesions smaller than
1 mm; mice with lesions with more than 20,000 parasites
and mice with lesions with less than 20,000 parasites.
Two × 2 contingency tables associating the numbers of
mice falling within the categories with one or another of
two experimental protocols (the protocol in which the
mice received 5 μg of extract and the protocol in which
they received 30 μg of the same extract; the protocol in
which the mice received 5 μg of extract and the protocol
in which they received 180 μg of the same extract; and the
protocol in which the mice received a given amount of
LaE and the protocol in which they received the sameamount of LbE) were constructed. Fisher’s exact probabil-
ity test was used to assess whether the frequency distribu-
tions of data within these tables were due to chance, since
that test was designed for contingency tables with a small
sample size, like the one in the present study.
Results were considered significant when the value of
P was ≤0.05 divided by the number of pairs of compared
datum sets in the statistical test.
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